bluebird bio has appointed O. James Sterling as Chief Financial Officer. Hanold Associates’ Adam Watson, Maisha Pearson and Catie Nelson led the search.
As Chief Financial Officer, James will report directly to CEO Andrew Obenshain and lead the organization’s finance function. In this role, James will oversee all financial activities for bluebird, building a strategy and function that aligns financial operations directly with business goals. Prior to joining bluebird, James served as Chief Financial Officer at Renalytix.
bluebird bio is a biotech company leading clinical and research programs for sickle cell disease, beta-thalassemia and cerebral adrenoleukodystrophy, and it is actively advancing research to apply new technologies to these and other diseases. The company custom designs each of its therapies to address the underlying cause of disease and has developed in-depth and effective analytical methods to understand the safety of its lentiviral vector technologies and drive the field of gene therapy forward. bluebird now has the largest and deepest ex-vivo gene therapy data set in the world, setting the standard for the industry. Headquartered in Somerville, Massachusetts, bluebird has more than 375 employees and is listed on the NASDAQ as BLUE.
Catie Nelson of Hanold Associates said, “James brings a wealth of healthcare experience and capital markets knowledge, which will be instrumental in driving bluebird bio’s commercialization efforts. His impressive track record and strategic insight make him a valuable addition to their team. Getting to know James has been a pleasure. We’re confident he will continue to drive meaningful results in the years ahead, and we look forward to watching the company’s continued growth.”